|
|
||||||||



* Department of Internal Medicine I and
Division of Hematology and Oncology, Department of Internal Medicine I, Regensburg, Germany; and
Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama, Birmingham, AL 35294
Several in vitro and animal studies have been performed to modulate the interaction of APCs and T cells by Fas (CD95/Apo-1) signaling to delete activated T cells in an Ag-specific manner. However, due to the difficulties in vector generation and low transduction frequencies, similar studies with primary human APC are still lacking. To evaluate whether Fas ligand (FasL/CD95L) expressing killer APC could be generated from primary human APC, monocyte-derived dendritic cells (DC) were transduced using the inducible Cre/Loxp adenovirus vector system. Combined transduction of DC by AdLoxpFasL and AxCANCre, but not single transduction with these vectors, resulted in dose- and time-dependent expression of FasL in >70% of mature DC (mDC), whereas <20% of immature DC (iDC) expressed FasL. In addition, transduction by AdLoxpFasL and AxCANCre induced apoptosis in >80% of iDC, whereas FasL-expressing mDC were protected from FasL/Fas (CD95/Apo-1)-mediated apoptosis despite coexpression of Fas. FasL-expressing mDC eliminated Fas+ Jurkat T cells as well as activated primary T cells by apoptosis, whereas nonactivated primary T cells were not deleted. Induction of apoptosis in Fas+ target cells required expression of FasL in DC and cell-to-cell contact between effector and target cell, and was not dependent on soluble FasL. Induction of apoptosis in Fas+ target cells required expression of FasL in DC, cell-to-cell contact between effector and target cell, and was not dependent on soluble FasL. The present results demonstrate that FasL-expressing killer APC can be generated from human monocyte-derived mDC using adenoviral gene transfer. Our results support the strategy to use killer APCs as immunomodulatory cells for the treatment of autoimmune disease and allograft rejection.
This article has been cited by other articles:
![]() |
C. Schutz, M. Fleck, A. Mackensen, A. Zoso, D. Halbritter, J. P. Schneck, and M. Oelke Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells Blood, April 1, 2008; 111(7): 3546 - 3552. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kawasaki, W. J. Hubbard, M. A. Choudhry, M. G. Schwacha, K. I. Bland, and I. H. Chaudry Trauma-Hemorrhage Induces Depressed Splenic Dendritic Cell Functions in Mice J. Immunol., October 1, 2006; 177(7): 4514 - 4520. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hoves, S. W. Krause, C. Schutz, D. Halbritter, J. Scholmerich, H. Herfarth, and M. Fleck Monocyte-Derived Human Macrophages Mediate Anergy in Allogeneic T Cells and Induce Regulatory T Cells J. Immunol., August 15, 2006; 177(4): 2691 - 2698. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Dauer, K. Schad, J. Junkmann, C. Bauer, J. Herten, R. Kiefl, M. Schnurr, S. Endres, and A. Eigler IFN-{alpha} promotes definitive maturation of dendritic cells generated by short-term culture of monocytes with GM-CSF and IL-4 J. Leukoc. Biol., August 1, 2006; 80(2): 278 - 286. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Vassiliou, V. Sharma, H. Jing, F. Sheibanie, and D. Ganea Prostaglandin E2 Promotes the Survival of Bone Marrow-Derived Dendritic Cells J. Immunol., December 1, 2004; 173(11): 6955 - 6964. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Bohana-Kashtan and C. I. Civin Fas Ligand as a Tool for Immunosuppression and Generation of Immune Tolerance Stem Cells, November 1, 2004; 22(6): 908 - 924. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |